Zydus receives ANDA approval for Dextroamphetamine IR Tabs

The estimated sales for Dextroamphetamine IR Tabs is $40.6 mn as per IMS

Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received its first ANDA approval from the USFDA to market Dextroamphetamine IR Tabs. The drug falls in the CNS stimulant segment and is the first product to be developed by the R&D team at Nesher.

The drug will be produced at the manufacturing facility based at St. Louis, Missouri, USA. The estimated sales for Dextroamphetamine IR Tabs is $40.6 mn as per IMS.

Nesher has considerable expertise in niche therapies which have development or production barriers, such as controlled release medications or DEA-controlled substances, which otherwise cannot be imported